Structure Therapeutics Reports Strong Aleniglipron Phase 2b Data, $1.4B Cash Runway, and Strategic Licensing Deals in Annual Report

summarizeSummary

Structure Therapeutics' 2025 annual report reveals positive Phase 2b results for its lead obesity drug, aleniglipron, a strong cash position of $1.4 billion extending through 2028, and substantial non-dilutive licensing revenue, signaling significant progress and financial stability.

check_boxKey Events · Earnings and Guidance · GPCR

• Positive Aleniglipron Phase 2b Clinical Data

  The lead oral GLP-1R agonist, aleniglipron, demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss of 11.3% (120mg dose) and 15.3% (240mg dose) at 36 weeks in Phase 2b studies, with plans to initiate Phase 3 in H2 2026.

• Strong Cash Position and Extended Runway

  The company reported $1.4 billion in cash, cash equivalents, and short-term investments as of December 31, 2025, projected to fund operations and key clinical milestones through the end of 2028.

• Significant Non-Dilutive Licensing Revenue

  Received a $100 million upfront payment from Genentech/Roche for a non-exclusive patent license and $10.2 million from Exelixis for the sale of early-stage assets, providing substantial non-dilutive capital.

• Successful Capital Raises

  Completed a $701.5 million net proceeds follow-on offering and sold $55.8 million net proceeds through an At-the-Market (ATM) offering in 2025, significantly boosting liquidity.

auto_awesomeAnalysis · GPCR · Life Sciences

Structure Therapeutics' annual report for 2025 highlights significant clinical advancements for its lead obesity candidate, aleniglipron, with Phase 2b data showing clinically meaningful weight loss (up to 15.3% at 36 weeks) and plans to initiate Phase 3 in the second half of 2026. The company also reported a robust financial position with $1.4 billion in cash, cash equivalents, and short-term investments, providing a runway through the end of 2028. This strong liquidity was bolstered by a $701.5 million follow-on offering, a $55.8 million ATM offering, and significant non-dilutive revenue from a $100 million upfront payment from Genentech/Roche for a non-exclusive patent license and $10.2 million from Exelixis for asset sales. The remediation of a previously identified material weakness in internal controls further strengthens the company's operational foundation. These developments collectively de-risk the company's ambitious pipeline and provide a clear path forward for its lead programs.